Biocon Biologics to offer 15% stake to Serum Institute Life Sciences

By Sumit Blogs -

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, said on Thursday that it will offer about 15% stake to Serum Institute Life Sciences Pvt Ltd (SILS), a subsidiary of Serum Institute of India, at a post-money valuation of $4.9 billion.

In return, BBL will get committed access to 100 million doses of vaccines annually for 15 years and commercialisation rights of SILS’ vaccine portfolio – including Covid-19 vaccines – for global markets, primarily from from SILS’ upcoming vaccine facility in Pune.

BBL will generate a committed revenue stream and related margins, starting from the second half of FY23. The company said Adar Poonawalla, CEO of Serum Institute of India (SII), will have a Board seat in BBL.

BBL will issue shares and receive the contemplated rights through a merger with Covidshield Technologies Pvt Ltd (CTPL), a wholly owned subsidiary of SILS, it said.

The board of directors of BBL approved the merger at its meeting held on September 16, BBL said in a regulatory filing on Thursday.

Kiran Mazumdar-Shaw, executive chairperson, Biocon & Biocon Biologics, said, “This alliance will complement the strengths and resources of the two leading players in vaccines and biologics. Our shared vision of building large scale businesses having global impact makes it a unique and synergistic value creation opportunity.”

The company said in the filing that BBL and CTPL will finalise the scheme of merger within 60 days and file the same with the jurisdictional National Company Law Tribunal (NCLT).

“We look forward to complementing each other’s capabilities and capacities in vaccines and biologics, with the objective of addressing inequitable access both in emerging and developed markets for life saving vaccines and biologics,” Poonawalla said.

The BBL management has scheduled an investors’ call on Friday.

In addition to vaccines, the strategic alliance will also develop antibodies targeting several infectious diseases including dengue, HIV, etc.

“The two companies will enter Service Level Agreements (SLAs) for manufacturing and distribution of the vaccines and antibodies,” it added.

BBL said vaccines are a “complementary business” fit and provides a new dimension to its effort in improving global healthcare.

Earlier, BBL had announced a manufacturing and commercialization partnership in emerging markets with Boston-based Adagio Therapeutics Inc for its novel Covid-19 antibody therapy, ADG20.

Credits – Source – https://ift.tt/2XokJ7W

The post Biocon Biologics to offer 15% stake to Serum Institute Life Sciences appeared first on Stay in Gurgaon.

Comments

Post a Comment

Popular posts from this blog

Flat sale of flu drugs hints at no unusual rise in infections

By Sumit Blogs -
Image
By Economic Times – Flat sale of flu drugs hints at no unusual rise in infections Industry executives and chemists said the April sales data showed a month-on-month decline of 30-40%. But even though the lockdown is seen to be impacting sales of most drugs, the pattern for medicines for infections and flus is no different.Last Updated: Apr 30, 2020, 11.23 AM ISTAgenciesExperts said the decline in sales was primarily because of the lockdown and other restrictions which forced people to stay indoors. (This story originally appeared in on Apr 30, 2020)NEW DELHI: Sales of anti-infectives (antibiotics and antivirals), respiratory drugs, painkillers and analgesics — some key medicines used for influenza-like illnesses — have remained mostly unchanged in last three months (January to March), partly explained by the lockdown but also indicating no unusual rise in flu-type infections that might point to a wider and undetected spread of Covid-19. Sales of most medicines, including this set of
Read more

10YearsForSimha: Reasons behind film’s success

By Sumit Blogs -
Image
By Times of India – 10YearsForSimha: Reasons behind film’s success TIMESOFINDIA.COM | Last updated on – Apr 30, 2020, 06:00 ISTclose01/6Take a look at the reasons behind the film’s successDirected by Boyapati Srinu, the 2010 film Simha was a game-changer among Tollywood films that was lauded, not only for Nandamuri Balakrishna’s intense performance in the dual role but also the gripping narration of the filmmaker. Balayya and Nayanthara were seen on the big screen for the first time ever in the film. The action drama made a special place in the hearts of the audience because of its simple storytelling, superhit songs and unbeatable chemistry between the lead pair. The movie has completed a decade, but the essence is as fresh as it was back then. As the film clocks 10 years of its release, find out the reasons behind the massive success of the Balakrishna starrer.readmore02/6​Boyapati Srinu’s gripping narrationBefore Simha, Boyapati Srinu had delivered Bhadra (2005) and Tulasi (2007),
Read more

Hrithik-Saif’s Vikram Vedha hits a roadblock

By Sumit Blogs -
Image
The stage was about to be set for Hrithik Roshan and Saif Ali Khan’s ‘Vikram Vedha’ in Mumbai’s Film City. The material had reached. The artisans had been hired. But the lights have now been dimmed. Madhavan and Vijay Sethupathi’s hit movie Vikram Vedha’s Hindi remake will not go on floors by mid-July as per the original plan. The new delta virus of COVID has sent shudders down many spines and many films which were being laid out on an expansive scale have been either held back or shifted their shoots abroad. The first schedule of this Hrithik-Saif movie will now be shot abroad. A source says, “The Mumbai schedule will be done but later.” Adds the source, “It’s a call that was taken yesterday. It wasn’t an easy call to take, no doubt, but the fact that it’s going to be a costly set made the makers take the safer route rather than be sorry later.” When contacted, General Secretary of FWICE (Federation of Western India Cine Employees), Ashok Dubey, confirmed that the makers of ‘V
Read more